- Record: found
- Abstract: found
- Article: not found
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Winette T A van der Graaf
1 ,
Jean-Yves Blay ,
Sant P Chawla ,
Dong-Wan Kim ,
Binh Bui-Nguyen ,
Paolo G Casali ,
Patrick Schöffski ,
Massimo Aglietta ,
Arthur P Staddon ,
Yasuo Beppu ,
Axel Le Cesne ,
Hans Gelderblom ,
Ian R Judson ,
Nobuhito Araki ,
Monia Ouali ,
Sandrine Marreaud ,
Rachel Hodge ,
Mohammed R Dewji ,
Corneel Coens ,
George D Demetri ,
Christopher D Fletcher ,
Angelo Paolo Dei Tos ,
Peter Hohenberger
May 19 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.